3 Huge Red Flags From Tilray's Q1 Earnings Report

Axe Cap view

Tilray’s Q1 Unveils Growing Pains, Not Growth

Rising costs and declining core revenue suggest caution on Tilray despite headline revenue growth.

Tilray’s latest earnings paint a troubling picture. While revenue grew, the roots of that growth are shaky. Their core cannabis revenue fell 13%, and operating expenses shot up 83%, far outpacing sales. Even more concerning is the cash burn ballooning from $1.3 million to $16.5 million year-on-year. Essentially, Tilray relies heavily on acquisitions like BrewDog to paper over business weakness, rather than organic strength. For South African investors, it’s a reminder to be wary of companies growing through relentless acquisitions rather than sustainable profitability. Tilray’s approach contrasts with peers that focus on trimming costs rather than ramping spending. If you are tracking global assets, the rand might weaken slightly on risk-off flows; USD/ZAR could test higher in the short term as investors pull out. But this view might be wrong if Tilray’s acquisitions start paying off faster than expected or if regulatory shifts boost cannabis demand. this is just our opinion and not financial advice